Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Hua Medicine

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dorzagliatin

            Therapeutic Area: Endocrinology Product Name: HMS5552

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bayer HealthCare

            Deal Size: $635.8 million Upfront Cash: $43.3 milllion

            Deal Type: Agreement August 17, 2020

            Details:

            Hua Medicine shall be responsible for clinical development, registration, product supply and distribution of dorzagliatin, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dorzagliatin,Metformin

            Therapeutic Area: Endocrinology Product Name: HMS5552

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dorzagliatin,Empagliflozin

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 26, 2020

            Details:

            The PK results showed no impact of dorzagliatin and empagliflozin on respective PK properties under co-administration, supporting the us of this combination in the clinical setting.